Z Gastroenterol 2003; 41(10): 1039-1045
DOI: 10.1055/s-2003-42922
Mitteilungen
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

ASCO Update 2003 - Highlights vom 39. Kongress der American Society of Clinical Oncology/ASCO 2003

ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003T. Eberl1 , U. Graeven2 , M. Heike3 , T. Höhler4 , M. P. Lutz5 , H. Messmann1 , T. Seufferlein6 , für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS
  • 1Medizinische Klinik III, Klinikum Augsburg
  • 2Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
  • 3Medizinische Klinik Mitte, Klinikum Dortmund
  • 4Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz
  • 5Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
  • 6Abt. Innere Medizin I, Universitätsklinikum Ulm
Further Information

Publication History

Publication Date:
16 October 2003 (online)

Wir möchten Ihnen auch dieses Jahr wieder die „Highlights” des diesjährigen ASCO-Meetings aus dem Bereich der gastrointestinalen Tumoren vorstellen. Dieser Bericht erhebt keinen Anspruch auf Vollständigkeit. Wir haben uns bemüht, solche Studien darzustellen, die in nächster Zeit unsere tägliche klinische Arbeit beeinflussen werden und die noch nicht anlässlich anderer Kongresse vorgestellt worden sind. Beim Nachlesen des einen oder anderen Abstracts wird möglicherweise auffallen, dass die unten angegebenen Zahlen sich manchmal etwas von den Zahlen im Abstract unterscheiden. Es ist eine Besonderheit dieses Kongresses, dass viele Studien auch nach Einreichung des Abstracts weiter ausgewertet werden und dann die aktuellsten Daten auf dem Meeting präsentiert werden. Diese Daten haben wir für unsere Übersicht verwendet.

Literatur

  • 1 Abid L, Oukkal M, Berkane S. et al . Phase II trial with the gemcitabine and cisplatin combination in the treatment of locally advanced and metastatic gall bladder carcinoma.  Proc ASCO. 2003;  22 1302
  • 2 Ajani J A, Van Cutsem E, Moiseyenko V. et al . Docetaxel (D), cisplatin, 5-fluorouracil ccompared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial.  Proc ASCO. 2003;  22 999
  • 3 Allum D, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial, ISRCTN 93 793 971).  Proc ASCO. 2003;  22 998
  • 4 Ardalan B, Livingstone A, Fancheschi D. et al . Neoadjuvant (NAD), adjuvant (AD) treatment without radiation in patients with advanced operable adenocarcinoma of esophagus.  Proc ASCO. 2003;  22 1309
  • 5 Armanios M Y, Xu R, Forastiere D G. et al . Phase II adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastroesophageal (GE) junction and cardia (E8296): A trial of the Eastern Cooperative Oncology Group.  Proc ASCO. 2003;  22 1190
  • 6 Bedenne P M, Michel O, Triboulet J P. et al . Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102).  Proc ASCO. 2002;  21 519
  • 7 Bonnetain F, Bedenne P, Michel P. et al . Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer.  Proc ASCO. 2003;  22 1001
  • 8 Bouche O, Raoul J L, Giovanini M. et al . Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinitecan in patients with metastastic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD9803.  Proc ASCO. 2003;  22 1002
  • 9 Burris H A, Moore M J, Andersen J. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial.  J Clin Oncol. 1997;  15 2403-2413
  • 10 Cebon J S, Findlay M, Hargreaves C. et al . Somatostatin receptor expression and clinical effects of octreotide LAR in patients with advanced hepatocellular carcinoma.  Proc ASCO. 2003;  22 1163
  • 11 Cunningham D, Humblet Y, Siena D. et al . Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).  Proc ASCO. 2003;  22 1012
  • 12 de Gramont A, Banzi M, Navarro M. et al . Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial.  Proc ASCO. 2003;  22 1015
  • 13 Frustaci S, Bearz A, Basso B. et al . Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcinoma (HCC).  Proc ASCO. 2003;  22 335
  • 14 Fujii M, Kosaki G, Tsuchiya S for the Gastric Cancer Chemotherapy Group of Japan. et al . Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer [Abstract].  Proc ASCO. 1999;  18 272
  • 15 Fung M C, Ishiguro H, Takayama S. et al . Survival Benefit of Chemotherapy Treatment in Advanced Pancreatic Cancer: A Meta-analysis.  Proc ASCO. 2003;  22 1155
  • 16 Gibson M K, Abraham S, Wu T T. et al . Epidermal growth factor receptor, p53 mutation and pathologi c response pedict survival in patients with locally advanced esophageal cancer treated with pre-operative chemotherapy.  Proc ASCO. 2003;  22 1030
  • 17 Hamburg S, Miller W, Garcia-Vargas J. et al . Survival benefit of nolatrexed in advanced hepatocellular carcinoma (aHCC).  Proc ASCO. 2003;  22 288
  • 18 Hawkins R, Cunningham D, Soerbye H. et al . Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC).  Proc ASCO. 2003;  22 257
  • 19 Hecht J R, Ajani A, Michaeli D. et al . A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease.  Proc ASCO. 2003;  22 1035
  • 20 Hegewisch-Becker S, Corovic A, Jaeger E. et al . Whole body hyperthermia (WBH, 41.8 C) combined with carboplatin and etoposide in advanced biliary tract cancer.  Proc ASCO. 2003;  22 311
  • 21 Heinemann V, Quietzsch D, Gieseler F. et al . A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma.  Proc ASCO. 2003;  22 1003
  • 22 Hsu C, Shen Y C, Yang C H. et al . Phase II study of weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.  Proc ASCO. 2003;  22 1322
  • 23 Hurwitz H, Fehrenbacher L, Cartwright T. et al . Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC.  Proc ASCO. 2003;  22 3646
  • 24 Ishii H, Furuse J, Nagase M. et al . Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: Results without stenting.  Proc ASCO. 2003;  22 1219
  • 25 Ishikura S, Ohtsu A, Shiaro K. et al . A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group study (JCOG9908-DI).  Proc ASCO. 2003;  22 1106
  • 26 Izzo F, Marra P, Beneduce G. et al . Phase I/II testing of pegylated arginine deiminase in subjects with hepatocellular carcinoma.  Proc ASCO. 2003;  22 1474
  • 27 Jacobson S D, Alberts S R, Mahoney M R. et al . Phase II trial of gemcitabine (Gem), 5-fluorouracil (5FU), and leucovorin (LV) in patients with unresectable or metastatic biliary (Bili) and gallbladder (GB) carcinoma: A North Central Cancer Treatment Group (NCCTG) study.  Proc ASCO. 2003;  22 1102
  • 28 Kang Y K, Choi D W, Im Y H. et al . A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer.  Proc ASCO. 1996;  15 215
  • 29 Kato H, Udagawa H, Togo A. et al . A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9780).  Proc ASCO. 2003;  22 1147
  • 30 Kindler H L, Ansari R, Lester E. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC).  Proc ASCO. 2003;  22 1037
  • 31 Köhne C H, Van Cutsem E, Wils J A. et al . Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40 986.  Proc ASCO. 2003;  22 1018
  • 32 Lee J L, Kim S B, Jung H Y. et al . A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery (CRT-S) versus surgery (S) alone for stage II, III respectable esophageal squamous cell carcinoma (SCC): An interim analysis.  Proc ASCO. 2003;  22 1043
  • 33 Leung T WT, Mo F, Leow C K. et al . Multicenter validation of the Chinese University Prognostic Index (CUPI) for hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1040
  • 34 Louvet C, Labianca R, Hammel P. et al . Gemcitabine versus GEMOX (gemcitabine + oxalipaltin) in non resectable pancreatic adenocarcinom: Interim results of the GERCOR/GISCAD Intergroup Phase III.  Proc ASCO. 2003;  22 1004
  • 35 Mal F, Perniceni H, Levard E. et al . Predictive factors of post operative early redux of oesophageal or cardial adenocarcinoma: A retrospective study in 100 patients.  Proc ASCO. 2003;  22 1350
  • 36 Mantravadi R VP, Fineberg N, Ansari A. et al . A phase Ii study of cisplatin, 5-fluorouracil (5-FU), radiation 8RT) and celecoxib in patients with resectable esophageal cancer 8EC): Preliminary results from the Hoosier Oncology Group (HOG).  Proc ASCO. 2003;  22 1168
  • 37 Moehler M H, Siebler J, Hoehler T. et al . Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.  Proc ASCO. 2003;  22 1034
  • 38 Muro K, Ando N, Nishimaki T. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905).  Proc ASCO. 2003;  22 1112
  • 39 Nehls O, Oettle H, Hartmann J T. et al . Oxaliplatin plus capecitabine in advanced biliary system adenocarcinomas: A multicenter phase II trial.  Proc ASCO. 2003;  22 1126
  • 40 Rizk N, Akhurst R, Downey R J. et al . FDG PET scanning predicts tumor stage and survival in esophageal adenocarcinoma.  Proc ASCO. 2003;  22 1085
  • 41 Reyes-Vidal J, Gallardo J, Yanez E. et al . Gemcitabine (G) and cisplatin (C) in the treatment of patients (pts) with unresectable or metastatic gallbladder cancer: Results of the phase II GOCCHI study.  Proc ASCO. 2003;  22 1095
  • 42 Rocha-Lima C MS, Rotche R, Jeffery M. et al . A randomized phase 3 study comparing theefficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy.  Proc ASCO. 2003;  22 1005
  • 43 Ross P, Nicolson M, Cunningham D. et al . Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer.  J Clin Oncol. 2002;  20 1996-2004
  • 44 Scheithauer W, Schuell B, Dworan N. et al . Mitomycin C in combination with capecitabine or biweekly high dose gemcitabine in patients with advanced biliary tract cancer (ABC).  Proc ASCO. 2003;  22 1059
  • 45 Songun I, Keizer H J, Hermans J. et al . Chemotherapy for operable gastric cancer: results from the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG).  Eur J Cancer. 1999;  35 558-562
  • 46 Stahl M, Wilke H, Walz M K. et al . Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: Chemoradiation with and without surgery.  Proc ASCO. 2003;  22 1001
  • 47 Stuart K, Eder J P, Proper J. et al . Phase II trial of irofulven in patients with unresectable hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1107
  • 48 Sumpter K A, Harper-Wynne C, Cunningham D. et al . Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation.  Proc ASCO. 2003;  22 1031
  • 49 Sun Y, Li H, Lin Z. et al . Phase I and pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152 243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unresectable hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1448
  • 50 Tempero M, Plunkett W, Ruiz Van Haperen V. et al . Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma.  Proc ASCO. 1999;  18 1048
  • 51 Thongprasert S, Napapan S, Charoentum C. et al . Phase II study of gemcitabine plus cisplatin in biliary tract cancer.  Proc ASCO. 2003;  22 1221
  • 52 Treiber G, Heinrich U, Fostitsch P. et al . Palliative treatment of hepatocellular carcinoma (HCC) using octreotide, rofecoxib, or both.  Proc ASCO. 2003;  22 1281
  • 53 Tsuji A, Morita S, Horimi T. et al . A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced bile duct carcinoma.  Proc ASCO. 2003;  22 1484
  • 54 Webb A, Cunningham D, Scarffe J H. et al . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.  J Clin Oncol. 1997;  15 261-267
  • 55 Yang T S, Chang W C, Lin Y C. et al . A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma.  Proc ASCO. 2003;  22 1351

PD Dr. Thomas Seufferlein

Abt. für Innere Medizin der Medizinischen Universitätsklinik Ulm

Robert-Koch-Straße 8

89081 Ulm

    >